

City. Docket No: 05618.P4124X

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Eugene T. Michal)	Examiner: Ford, Allison M.
)	
Application No.: 10/802,955)	Art Unit: 1651
)	
Filing Date: March 16, 2004)	
)	
For: METHODS AND COMPOSITIONS TO)	
TREAT MYOCARDIAL CONDITIONS)	
<hr/>		
Commissioner for Patents		
P.O. Box 1450		
Alexandria, Virginia 22313-1450		

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a copy of Information Disclosure Citation Form PTO-1449 or PTO/SB/08 together with copies of the documents cited on that form, except for copies not required to be submitted (e.g., copies of U.S. patents and U.S. published patent applications need not be enclosed). It is respectfully requested that the cited documents be considered and that the enclosed copy of Information Disclosure Citation Form PTO-1449 or PTO/SB/08 be initialed by the Examiner to indicate such consideration and a copy thereof returned to applicant(s).

Pursuant to 37 C.F.R. § 1.97, the submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed as an admission that the information cited in this statement is material to patentability.

Pursuant to 37 C.F.R. § 1.97, this Information Disclosure Statement is being submitted under one of the following (as indicated by an "X" to the left of the appropriate paragraph):

 X 37 C.F.R. §1.97(b).

_____ 37 C.F.R. §1.97(c). If so, then enclosed with this Information Disclosure Statement is one of the following:

_____ A statement pursuant to 37 C.F.R. §1.97(e) or

_____ A check for \$_____ for the fee under 37 C.F.R. § 1.17(p).

_____ 37 C.F.R. §1.97(d). If so, then enclosed with this Information Disclosure Statement are the following:


- (1) A statement pursuant to 37 C.F.R. §1.97(e); and
- (2) A check for \$_____ for the fee under 37 C.F.R. §1.17(p) for submission of the Information Disclosure Statement.

If there are any additional charges, please charge Deposit Account No. 02-2666.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP

Dated: 12/19, 2006


James C. Scheller, Jr.
Reg. No. 31,195

12400 Wilshire Blvd.
Seventh Floor
Los Angeles, CA 90025-1026
(408) 720-8300

EXPRESS MAIL CERTIFICATE OF MAILING

"Express Mail" mailing label number: EV 897 652 534 US Date of Deposit: December 19, 2006
I hereby certify that I am causing this paper or fee to be deposited with the United States Postal Service "Express Mail Post Office to Addressee" service on the date indicated above and that this paper or fee has been addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450

Connie Thayer
(Typed or printed name of person
mailing paper or fee)


(Signature of person mailing paper or fee)

12-19-06
(Date signed)

Substitute for Form 1449/PTO <div style="display: flex; align-items: center; justify-content: center;"> <div style="text-align: center;"> <h2 style="margin: 0;">INFORMATION DISCLOSURE</h2> <h2 style="margin: 0;">STATEMENT BY APPLICANT</h2> <p style="font-size: small; margin: 0;">(use as many sheets as necessary)</p> </div> </div>			Complete if Known	
Application Number		10/802,955		
Filing Date		March 16, 2004		
First Named Inventor:		Eugene T. Michal		
Art Unit		1651		
Examiner Name		Allison M. Ford		
Attorney Docket No.		005618.P4124X		

Sheet
of
10

U.S. PATENT DOCUMENTS						
Exmnr Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (If known)			
	1.	3,780,733	B1	12-25-1973	Martinez-Mangor	
	2.	4,617,186	B1	10-14-1986	Schafer	
	3.	4,794,931	B1	01-03-1989	Yock	
	4.	5,000,185	B1	03-19-1991	Yock	
	5.	5,024,234	B1	06-18-1991	Leary et al.	
	6.	5,049,130	B1	09-17-1991	Powell	
	7.	5,092,848	B1	03-03-1992	DeCiutiis	
	8.	5,171,217	B1	12-15-1992	March et al.	
	9.	5,202,745	B1	04-13-1993	Sorin et al.	
	10.	5,203,338	B1	04-20-1993	Jang	
	11.	5,270,300	B1	12-14-1993	Hunziker, E.B.	
	12.	5,291,267	B1	03-01-1994	Sorin et al.	
	13.	5,321,501	B1	06-14-1994	Swanson et al.	
	14.	5,336,252	B1	08-09-1994	Donald Cohen	
	15.	5,354,279	B1	10-11-1994	Hofling	
	16.	5,365,325	B1	11-15-1994	Kumasaka et al.	
	17.	5,372,138	B1	12-13-1994	Crowley et al	
	18.	5,380,292	B1	01-10-1995	Wilson	
	19.	5,437,632	B1	08-01-1995	Engelson	
	20.	5,459,570	B1	10-17-1995	Swanson et al.	
	21.	5,464,395	B1	11-07-1995	Faxon et al.	
	22.	5,465,147	B1	11-07-1995	Swanson	
	23.	5,485,486	B1	01-16-1996	Gilhausen et al.	
	24.	5,499,630	B1	03-19-1996	Hiki et al.	
	25.	5,540,912	B1	07-30-1996	Roorda, et al.	
	26.	5,546,948	B1	08-20-1996	Hamm et al.	
	27.	5,575,815	B1	11-19-1996	Siepian, et al.	
	28.	5,580,856	B1	12-03-1996	Prestrelski et al.	
	29.	5,588,432	B1	12-31-1996	Crowley	
	30.	5,621,610	B1	04-15-1997	More, P.M. et al.	
	31.	5,642,234	B1	06-24-1997	Altman et al.	

Examiner Signature	Date Considered
-----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Allison M. Ford
Sheet	2	of	10	Attorney Docket No.	005618.P4124X

	32.	5,655,548	B1	08-12-1997	Nelson et al.	
	33.	5,693,029	B1	12-02-1997	Leonhardt	
	34.	5,722,403	B1	03-03-1998	McGee et al.	
	35.	5,740,808	B1	04-21-1998	Panescu et al.	
	36.	5,785,689	B1	07-28-1998	De Toledo et al.	
	37.	5,827,313	B1	10-27-1998	Ream	
	38.	5,843,156	B1	12-01-1998	Slepian et al.	
	39.	5,879,713	B1	03-09-1999	Roth et al.	
	40.	5,900,433	B1	05-04-1999	Igo et al.	
	41.	5,935,160	B1	08-10-1999	Auricchio et al.	
	42.	5,939,323	B1	08-17-1999	Valentini et al.	
	43.	5,941,868	B1	08-24-1999	Kaplan et al.	
	44.	5,957,941	B1	09-28-1999	Ream	
	45.	5,968,064	B1	10-19-1999	Selmon et al.	
	46.	5,979,449	B1	11-09-1999	Steer, Eugene	
	47.	5,981,568	B1	11-09-1999	Kunz et al.	
	48.	5,997,536	B1	12-07-1999	Osswald et al.	
	49.	6,022,540	B1	02-08-2000	Bruder et al.	
	50.	6,045,565	B1	04-04-2000	Ellis et al.	
	51.	6,051,071	B1	04-18-2000	Charvet et al.	
	52.	6,056,744	B1	05-02-2000	Edwards	
	53.	6,058,329	B1	05-02-2000	Salo et al.	
	54.	6,071,305	B1	06-06-2000	Brown et al.	
	55.	6,086,582	B1	07-11-2000	Altman et al.	
	56.	6,093,177	B1	07-25-2000	Javier, Jr. et al.	
	57.	6,099,563	B1	08-08-2000	Sheng-Ping Zhong	
	58.	6,099,864	B1	08-08-2000	Morrison et al.	
	59.	6,102,887	B1	08-15-2000	Altman	
	60.	6,102,904	B1	08-15-2000	Vigil et al.	
	61.	6,102,926	B1	08-15-2000	Tartaglia et al.	
	62.	6,120,520	B1	09-19-2000	Saadat et al.	
	63.	6,120,904	B1	09-19-2000	Hostettler et al.	
	64.	6,133,231	B1	10-17-2000	Ferrara et al.	
	65.	6,134,003	B1	10-17-2000	Tearney et al.	
	66.	6,152,141	B1	11-28-2000	Stevens et al.	
	67.	6,159,443	B1	12-12-2000	Hallahan	
	68.	6,175,669	B1	01-16-2001	Colston et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Allison M. Ford
Sheet	3	of	10	Attorney Docket No.	005618.P4124X

	69.	6,177,407	B1	01-23-2001	Rodgers et al.	
	70.	6,179,809	B1	01-30-2001	Khairkhahan et al.	
	71.	6,183,432	B1	02-06-2001	Milo	
	72.	6,183,444	B1	02-06-2001	Glines et al.	
	73.	6,187,330	B1	02-13-2001	Wang et al.	
	74.	6,190,353	B1	02-20-2001	Makower et al.	
	75.	6,191,144	B1	02-20-2001	Isner	
	76.	6,193,763	B1	02-27-2001	Mackin	
	77.	6,197,324	B1	03-06-2001	Crittenden	
	78.	6,201,608	B1	03-13-2001	Mandella et al.	
	79.	6,206,893	B1	03-27-2001	Klein et al.	
	80.	6,206,914	B1	03-27-2001	Soykan et al.	
	81.	6,207,180	B1	03-27-2001	Ottoboni et al.	
	82.	6,210,392	B1	04-03-2001	Vigil et al.	
	83.	6,217,527	B1	04-17-2001	Selmon et al.	
	84.	6,217,554	B1	04-17-2001	Green	
	85.	6,221,049	B1	04-24-2001	Selmon et al.	
	86.	6,231,546	B1	05-15-2001	Milo et al.	
	87.	6,235,000	B1	05-22-2001	Milo et al.	
	88.	6,241,710	B1	06-05-2001	VanTassel et al.	
	89.	6,251,104	B1	06-26-2001	Kesten, et al.	
	90.	6,283,947	B1	09-04-2001	Daryush Mirzaee	
	91.	6,287,285	B1	09-11-2001	Michal, et al.	
	92.	6,290,729	B1	09-18-2001	Slepian et al.	
	93.	6,296,602	B1	10-02-2001	Headley	
	94.	6,299,604	B1	10-09-2001	Ragheb et al.	
	95.	6,309,370	B1	10-30-2001	Haim et al.	
	96.	6,315,994	B1	11-13-2001	Usala et al.	
	97.	6,334,872	B1	01-01-2002	Termin et al.	
	98.	6,346,098	B1	02-12-2002	Yock et al.	
	99.	6,346,099	B1	02-12-2002	Altman	
	100.	6,346,515	B1	02-12-2002	Pitaru et al.	
	101.	6,358,247	B1	03-19-2002	Altman et al.	
	102.	6,358,258	B1	03-19-2002	Arcia et al.	
	103.	6,368,285	B1	04-09-2002	Osadchy et al.	
	104.	6,371,935	B1	04-16-2002	Macoviak et al.	
	105.	6,371,992	B1	04-16-2002	Tanagho et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Allison M. Ford
Sheet	4	of	10	Attorney Docket No.	005618.P4124X

	106.	6,379,379	B1	04-30-2002	Wang	
	107.	6,385,476	B1	05-07-2002	Osadchy et al.	
	108.	6,391,052	B1	05-21-2002	Buirge et al.	
	109.	6,395,023	B1	05-28-2002	Summers	
	110.	6,409,716	B1	06-25-2002	Sahatjian et al.	
	111.	6,416,510	B1	07-09-2002	Altman et al.	
	112.	6,432,119	B1	08-13-2002	Saadat	
	113.	6,436,135	B1	08-20-2002	Goldfarb	
	114.	6,443,941	B1	09-03-2002	Slepian et al.	
	115.	6,443,949	B1	09-03-2002	Altman	
	116.	6,447,504	B1	09-10-2002	Ben-Haim et al.	
	117.	6,464,862	B1	10-15-2002	Bennett et al.	
	118.	6,478,776	B1	11-12-2002	Rosenman et al.	
	119.	6,482,231	B1	11-19-2002	Abatangelo et al.	
	120.	6,485,481	B1	11-26-2002	Pfeiffer	
	121.	6,548,081	B1	04-15-2003	Sadozai et al.	
	122.	6,554,801	B1	04-29-2003	Steward et al.	
	123.	6,599,267	B1	07-29-2003	Ray et al.	
	124.	6,628,988	B1	09-30-2003	Kramer et al.	
	125.	6,629,947	B1	10-07-2003	Sahatjian et al.	
	126.	6,632,457	B1	10-14-2003	Sawhney, A.S.	
	127.	6,635,267	B1	10-21-2003	Miyoshi et al.	
	128.	6,660,034	B1	12-09-2003	Mandrusov et al.	
	129.	6,682,730	B1	01-27-2004	Mickle et al.	
	130.	6,689,608	B1	02-10-2004	Mikos et al.	
	131.	6,692,466	B1	02-17-2004	Chow et al.	
	132.	6,702,744	B1	03-09-2004	Mandrusov et al.	
	133.	6,706,034	B1	03-16-2004	Bhat, Vinayak D.	
	134.	6,737,072	B1	05-18-2004	Angele, P., et al.	
	135.	6,748,258	B1	06-08-2004	Mueller et al.	
	136.	6,749,617	B1	06-15-2004	Palasis et al.	
	137.	6,777,231	B1	08-17-2004	Katz et al.	
	138.	6,790,455	B1	09-14-2004	Chu et al.	
	139.	6,858,229	B1	02-22-2005	Hubbell et al.	
	140.	2001/0023349	A1	9-20-2001	VanTassel et al.	
	141.	2002/0146557	A1	10-10-2002	Claude et al.	
	142.	2003/0040712	A1	02-27-2003	Ray et al.	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Allison M. Ford
Sheet	5	of	10	Attorney Docket No.	005618.P4124X

	143.	2003/0078671	A1	04-24-2003	Lesniak et al.	
	144.	2004/0208845	A1	10-21-2004	Michal, et al.	
	145.	2004/0213756	A1	10-28-2004	Michal, et al.	
	146.	2005/0031874	A1	02-10-2005	Michal, et al.	
	147.	RE37,463		12-25-1973	Menke	

FOREIGN PATENT DOCUMENTS

Exmnr Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Code ⁵	Number ⁴	Kind (if known)				
	148.	EP	0691603	A1	01-10-1996	Compaq Computer Corp.		
	149.	EP	0861632	A1	09-02-1998	Nissho Corporation		
	150.	EP	0938871	A2	09-01-1999	Eclipse Surgical Technologies, Inc.		
	151.	GB	2194144	A1	03-02-1988	American Cyanamid Company		
	152.	WO	00/71196	A1	11-30-2000	Micro Therapeutics, Inc.		
	153.	WO	01/24775	A1	04-12-2001	Essentia Biosystems, Inc.		
	154.	WO	01/45548	A2	06-28-2001	Tricardia, Inc.		
	155.	WO	01/49357	A2	07-12-2001	Advanced Cardiovascular System		
	156.	WO	02/28450	A2	04-11-2002	Spence, Paul. A, et al.		
	157.	WO	03/027234	A2	04-03-2003	Curis, Inc.		
	158.	WO	03/064037	A1	08-07-2003	Medtronic		
	159.	WO	2004/050013	A2	06-17-2004	Lee, R., et al.		
	160.	WO	2004/066829	A2	08-12-2004	Origin Medsystems		
	161.	WO	2004/091592	A2	10-28-2004	Guidant Corporaiton, V.I.		
	162.	WO	92/10142	A1	06-25-1992	Pfizer Hosp. Products Group		
	163.	WO	98/54301	A2	12-3-1998	Mickle, D.A., et al.		

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/802,955	
			Filing Date	March 16, 2004	
			First Named Inventor:	Eugene T. Michal	
			Art Unit	1651	
			Examiner Name	Allison M. Ford	
Sheet	6	of	10	Attorney Docket No.	005618.P4124X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	164.	Agocha A. et al. "Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: effects of transforming growth factor-beta 1, thyroid hormone, angiotensin II and fibroblast growth factor," <u>J. Mol. Cell. Cardiol.</u> (1997) 29(8): 2233-2244.	
	165.	Anderson, J. et al. "Biodegradation and Biocompatibility of PLA and PLGA Microspheres," <u>Advanced Drug Delivery Reviews</u> 28 (1997), pp.5-24.	
	166.	Baxter, "FloSeal Matrix Hemostatic Sealant," downloaded from the Internet on November 14, 2002, from: http://www.fusionmed.com/docs/surgeon/default.asp , 2 pages.	
	167.	Berger et al. "Poly-L-cysteine," <u>J. Am. Chem. Soc.</u> 78, p. 4483-4488 (1956).	
	168.	Bernatowicz, M. et al. "Preparation of Boc-[S-(3-nitro-2-pyridinesulfonyl)]-cysteine and its use for Unsymmetrical Disulfide Bond Formation," <u>Int. J. Peptide Protein Res.</u> (1986), 28(2):107-112.	
	169.	Boland, E.D. "Electrospinning Collagen and Elastin: Preliminary Vascular Tissue Engineering" <u>Frontiers in Bioscience</u> 9, pp. 1422-1432, May 1, 2004.	
	170.	Brust, Gregory, "Polymides", www.psrc.usm.edu/macrog/imide.htm , 4 pages	
	171.	Buschmann, I. et al. "Arteriogenesis Versus Angiogenesis: Two Mechanisms of Vessel Growth," <u>News Physio. Sci.</u> 14 (June 1999), pp.121-125.	
	172.	Canderm Pharma, "Technical Dossier: Artecoll," downloaded from the Internet on October 22, 2002 from: http://www.canderm.com/artecoll/tech.html , 3 pages.	
	173.	Carpino, L. et al. "Tris (2-Aminoethyl)amine as a Substitute for 4-(Aminomethyl)piperidine in the Fmoc/Polyamine Approach to Rapid Peptide Synthesis," <u>J. Org. Chem.</u> 55 (1990), pp. 1673-1675.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Allison M. Ford
Sheet	7	of	10	Attorney Docket No.	005618.P4124X

174.	Chandy et al. "Development of Porous Alignate/Elastin/PEG Composite Matrix for Cardiovascular Engineering," <u>J. Biomat. Appl.</u> 17 (2003), pp. 287-301.
175.	Corbett, S. et al. "Covalent Cross-linking of Fibronectin to Fibrin is Required for Maximal Cell Adhesion to a Fibronectin-Fibrin Matrix," <u>The Journal of Biological Chemistry</u> (October 3, 1997), 272(40):24999-25005.
176.	Creemers, E. et al. "Matrix Metalloproteinase Inhibition After Myocardial Infarction, A New Approach to Prevent Heart Failure?" <u>Cir. Res.</u> Vol. 89, (2001), pp. 201-210.
177.	Crivello, et al. "Synthesis and Photoinitiated Cationic Polymerization of Monomers with the Silsesquioxane Core," <u>J Polym Science Part A Polym Chem</u> 35 (1997), pp. 407-425.
178.	Davis, M.E. et al., "Injectable Self-Assembling Peptide Nanofibers Create Intramyocardial Microenvironments for Endothelial Cells" <u>Circulation</u> 2005: 111:442-450
179.	Dinsbergs et al. "Cellular Response to Transforming Growth Factor - β 1 and Basic Fibroblast Growth Factor Depends on Release Kinetics & Extracellular Matrix Interactions," <u>J. Bio Chem</u> 271(47) Nov 22, pp. 29822-29829 (1996).
180.	Edelman, E.R. et al. "Controlled & Modulated Release of Basic Fibroblast Growth Factor," <u>Biomaterials</u> 12 (1991), p. 619-626.
181.	Fukumoto, S. et al. "Protein Kinase C δ Inhibits the Proliferation of Vascular Smooth Muscle Cells by Suppressing G1 Cyclin Expression," <u>The Journal of Biological Chemistry</u> (May 23, 1997), 272(21):13816-13822.
182.	Giordano, F. et al. "Angiogenesis: The Role of the Microenvironment in Flipping the Switch," <u>Current Opinion in Genetics and Development</u> (2001), 11:35-40.
183.	Gossler, et al. (1986), <u>Proc. Natl. Acad. Sci. USA</u> , 83:9065-9069.
184.	Grafe, T.H., "Nanofiber Webs from Electrospinning" Presented at the Nonwovens in Filtration - Fifth International Conference, Stuttgart, Germany, March 2003, pg. 1-5.
185.	Grund, F. et al. "Microembolization in Pigs: Effects on Coronary Blood Flow and Myocardial Ischemic Tolerance," <u>AM J. Physiol.</u> 277 (1999), pp. H533-H542.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/802,955	
			Filing Date	March 16, 2004	
			First Named Inventor:	Eugene T. Michal	
			Art Unit	1651	
			Examiner Name	Allison M. Ford	
Sheet	8	of	10	Attorney Docket No.	005618.P4124X

186.	Gupta et al. "Changes in Passive Mechanical Stiffness of Myocardial Tissue with Aneurysm Formation," <u>Circulation</u> (May 1994), 89(5):2315-2326.
187.	Hashimoto, T. et al. "Development of Alginate Wound Dressings Linked with Hybrid Peptides Derived from Laminin and Elastin," <u>Biomaterials</u> 25 (2004), pp. 1407-1414.
188.	Heeschen et al. "Nicotine Stimulates Tumor Angiogenesis", Abstract, American College of Cardiology 50th Annual Scientific Session, Stanford, California, March 18, 2001 (1 page)
189.	Helisch, A. et al. "Angiogenesis and Arteriogenesis--Not yet for prescription," NEUE DIAGNOSTISCHE UND THERAP. VERFAHREN, Z. Kardio 89:239-244 Steinkopff Verlag (2000).
190.	Hendel, R.C., et al. "Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion. Evidence for a Dose-Dependent Response" <u>Circulation</u> 101:118-121, 2000
191.	Huang, K. et al. "Synthesis and Characterization of Self-Assembling Block Copolymers Containing Bioadhesive End Groups," <u>Biomacromolecules</u> (2002), 3(2):397-406.
192.	Hutcheson, et al. "Comparison of Benefits on Myocardial Performance of Cellular Cardiomyoplasty with Skeletal Myoblasts and Fibroblasts," <u>Cell Transplant</u> (2000), 9(3):359-68.
193.	Ito, W. D. et al. "Monocyte Chemotactic Protein-1 Increases Collateral and Peripheral Conductance After Femoral Artery Occlusion," <u>Circulation Research</u> (June 1997), 80(6):829-837.
194.	Johnson, O.L. et al. "The Stabilization & Encapsulation of Human Growth Hormone into Biodegradable Microspheres," <u>Pharm Res.</u> 14(6):730-735 (1997).
195.	Källtorp, M. et al. "Inflammatory Cell Recruitment, Distribution, and Chemiluminescence Response at IgG Precoated- and Thiol Functionalized Gold Surfaces," Swedish Biomaterials Consortium, Swedish Foundation for Strategic Research, <u>J. Biomed. Mater. Res.</u> , 1999 John Wiley & Sons, Inc., pages 251-259.
196.	Kawai, K. et al. "Accelerated Tissue Regeneration Through Incorporation of Basic Fibroblast Growth Factor-Impregnated Gelatin Microspheres into Artificial Dermis," <u>Biomaterials</u> 21 (2000), pp. 489-499.
197.	Kelley et al. "Restraining Infarct Expansion Preserves Left Ventricular Geometry and Function After Acute Anteroapical Infarction," <u>Circ.</u> (1999), 99:135-142.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/802,955	
			Filing Date	March 16, 2004	
			First Named Inventor:	Eugene T. Michal	
			Art Unit	1651	
			Examiner Name	Allison M. Ford	
Sheet	9	of	10	Attorney Docket No.	005618.P4124X

	198.	Kelly, E.B. "Advances in Mammalian and Stem Cloning," <u>Genetic Engineering News</u> , Vol. 23, Number 7, April 1, 2003, 2 pages.	
	199.	Kim, D. et al. "Glow Discharge Plasma Deposition (GDPD) Technique for the Local Controlled Delivery of Hirudin from Biomaterials," <u>Pharmaceutical Research</u> (1998), 15(5):783-786.	
	200.	Klugherz, B. et al. "Gene Delivery From a DNA Controlled-Release Stent in Porcine Coronary Arteries," <u>Nature Biotechnology</u> 18 (November 2000), pp. 1181-1184.	
	201.	Kohilas, K. et al. "Effect of Prosthetic Titanium Wear Debris on Mitogen-Induced Monocyte and Lymphoid Activation," Johns Hopkins University, Dept. of Orthopaedic Surgery, <u>J. Biomed Mater Res.</u> 47 (April 1999), pp. 95-103.	
	202.	Kwok, Connie et al. "Design of Infection-Resistant Antibiotic-Releasing Polymers: I. Fabrication and Formulation," <u>Journal of Controlled Release</u> 62 (1999), pp. 289-299.	
	203.	Laham, R.J., "Intrapericardial Delivery of Fibroblast Growth Factor-2 Induces Neovascularization in a Porcine Model of Chronic Myocardial Ischemia," <u>J. Pharmacol Exper Therap</u> 292:795-802, 2000.	
	204.	Leor, J. et al. "Bioengineered Cardiac Grafts-A New Approach to Repair the Infarcted Myocardium?" <u>Circulation</u> (2000); 102[suppl III] III-56-III-61.	
	205.	Li, J. et al. "PR39, A Peptide Regulator of Angiogenesis," <u>Nature Medicine</u> (January 2000), 6(1):49-55.	
	206.	Lindsey et al. "Selective Matrix Metalloproteinase Inhibitors Reduce Left Ventricle Remodeling but does not Inhibit Angiogenesis after Myocardial Infarction," <u>Circulation</u> (Feb. 12, 2002), 105(6):753-8.	
	207.	Luo, Y. et al. "Cross-linked Hyaluronic Acid Hydrogel Films: New Biomaterials for Drug Delivery," <u>Journal of Controlled Release</u> (2000), 69:169-184.	
	208.	Lyman, M.D. et al. "Characterization of the Formation of Interfacially Photopolymerized Thin Hydrogels in Contact with Arterial Tissue," <u>Biomaterials</u> (Feb. 1996), 17(3):359-364.	
	209.	Sawhney, A.S. et al. "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(a-hydroxy acid) Diacrylate Macromers," <u>Macromolecules</u> (1993), pp. 26, 581-587.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/802,955	
			Filing Date	March 16, 2004	
			First Named Inventor:	Eugene T. Michal	
			Art Unit	1651	
			Examiner Name	Allison M. Ford	
Sheet	10	of	10	Attorney Docket No.	005618.P4124X

	210.	Shin, H. et al. "In Vivo Bone & Soft Tissue Response to Injectable, Biodegradable Eligio (Polyethylene Glycol Fumerate) Hydrogels," <u>Biomaterials</u> 24 (2003), pp. 3201-3211.	
	211.	Yamamoto, N. et al. "Histologic Evidence that Basic Fibroblast Growth Factor Enhances the Angiogenic Effects of Transmyocardial Laser Revascularization," <u>Basic Research in Cardiology</u> (February 2000), 95(1):55-63.	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.